Vyvgart

Argenx shrugs off myasthenia gravis threat from UCB as Vyvgart nears next potential launch
Fierce Pharma
Fri, 05/10/24 - 11:37 am
Argenx
myasthenia gravis
Vyvgart
Argenx dealt another blow as Vyvgart Hytrulo fails again
Pharmaphorum
Wed, 12/20/23 - 09:28 am
Argenx
Vyvgart
clinical trials
Vyvgart Hytrulo
pemphigus vulgaris
On blockbuster path, Argenx's red-hot Vyvgart comes up short in thrombocytopenia trial
Fierce Pharma
Wed, 11/29/23 - 12:02 pm
Argenx
Vyvgart
thrombocytopenia
clinical trials
Vyvgart shines in CIDP study, teeing up another potential nod for Argenx's pipeline in a product
Fierce Pharma
Tue, 07/18/23 - 10:29 am
Argenx
Vyvgart
clinical trials
CIDP
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
Mon, 12/12/22 - 10:56 pm
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Fierce Pharma
Tue, 09/27/22 - 10:16 am
Argenx
Vyvgart
myasthenia gravis
efgartigimod
FDA
As Vyvgart launch gains steam, Argenx CEO says his company can achieve 'standalone' success
Fierce Pharma
Wed, 09/14/22 - 09:41 am
Argenx
Vyvgart
innovation
myasthenia gravis
Argenx takes a step towards convenience
EP Vantage
Wed, 03/23/22 - 10:27 am
Argenx
efgartigimod
Vyvgart
myasthenia gravis
Go or no go? Roche’s fresh start for a new year
EP Vantage
Mon, 12/20/21 - 10:59 am
FDA
Roche
Novartis
Pfizer
AstraZeneca
Cibinqo
Lynparza
Tezspire
Vyvgart
faricimab